ABSTRACT: Expression data from colon cancer cell HCT116 mouse xenograft - Control vs. traditional Chinese medicine Astragalus membranaceus-treated conditions
Project description:To identify biomarkers regulated by traditional Chinese medicine Astragalus membranaceus Fischer Bge. var. mongolicus Bge. Hsiao in colorectal cancer. We have identified several differentially expressed genes including microRNAs using Affymetrix HTA-2.0 array. In this dataset, we include the expression data obtained from colon cancer cell line HCT116 grafted into nude mice. The mice was treated either water or traditional Chinese medicine Astragalus membranaceus for 28 days. These data are used to obtain 1425 genes that are differentially expressed in response to Astragalus membranaceus treatment.
Project description:A traditional Chinese medicine (TCM) formula, containing Astragalus membranaceus (Fisch.) Bunge, Aconitum wilsonii Stapf ex Veitch, Curcuma longa L., and Radix ophiopogonis (AACO), has clinically proven therapeutic value for the treatment of chronic heart failure (CHF). In this study, we explored the potential pharmacological mechanism underlying the activity of the AACO formula against CHF.
Project description:Astragali Radix (AR) is a commonly used herbal drug in Traditional Chinese Medicine, and widely used for the treatment of diabetes, cardiovascular diseases, nephropathy and neuropathy. The main source of AR is the dried root of Astragalus membranaceus var. mongholicus (Bge.) Hsiao in China, and both cultivated and wild ARs are used in the clinic. Systematic comparison of cultivated AR and wild AR should be performed to ensure the efficacy and safety in clinic. In this study, the chemical compositions of two different ARs, collected in Shanxi (wild) and Gansu (cultivated) Provinces, were compared by NMR based metabolic fingerprint coupled with multivariate analysis. Then SX-AR and GS-AR induced metabolic changes of endogenous metabolites in mice were also compared. The results showed that SX-AR and GS-AR differed significantly not only in the primary metabolites, but also the secondary metabolites. However, alterations of endogenous metabolites in serum, lung, liver and spleen were relatively small between them. This study provided a novel and valuable method for consistency and diversity evaluation of herbal drugs, and further studies should be conducted on the difference of polysaccharide as well as biological effect between the two kinds of ARs.
Project description:Autism spectrum disorder (ASD) represents a multifaceted set of neurodevelopmental conditions marked by challenges with social interaction and communication, restricted and repetitive behavior. Astragaloside IV (ASIV), a natural compound derived from the traditional Chinese herb Astragalus membranaceus, exhibits robust neuroprotective effects. However, whether ASIV can ameliorate behavioral deficits in ASD remains unknown. The present study found that ASIV treatment significantly reduced social deficits and repetitive behaviors in the BTBR T+tf/J (BTBR) mouse model of autism in a dose-dependent manner. The ASIV treatment normalized the neurotransmitter levels (GABA and glutamate) and their corresponding vesicular transporters (vGAT, vGlut1) in the medial prefrontal cortex (mPFC). Furthermore, whole-cell patch-clamp recordings showed that the imbalance between excitatory and inhibitory synaptic transmission in layer V of mPFC was reversed after ASIV administration. Mechanistically, bulk RNA-seq and PPI network analysis identified the CAMK2N2 as the crucial bridging gene regulating both oxidative phosphorylation and neurotransmission. CAMK2N2 overexpression in the mPFC abolished the beneficial effects of ASIV on autistic symptoms in BTBR mice via the CAMK2/CREB pathway. These findings suggest that ASIV may serve as a promising therapeutic option for ASD and imply that the CAMK2N2/CAMK2/CREB axis could be a potential target for these patients.
